Delta-fly pharma inc.: notice of authorization to conduct the phase i/ii study of dfp-10917 combined with venetoclax

Tokushima, japan--(business wire)--following to the previous information on march 11th, 2024, we are excited to share our latest development status. we are pleased to announce the protocol for the phase i/ii clinical trial of dfp-10917 combined with venetoclax (vtx) in patients with acute myeloid leukemia (aml) with prior vtx involved one regimen, which was submitted to the fda in us on march 8 has been approved by the fda in us dated april 8, 2024. accordingly, we can start the phase i/ii comb.
DAL Ratings Summary
DAL Quant Ranking